Late-occurring toxicity induced by an immune checkpoint blockade in adjuvant treatment of a stage III melanoma patient

Eur J Cancer. 2018 May:95:130-132. doi: 10.1016/j.ejca.2018.02.019. Epub 2018 Mar 17.

Authors

Mario Mandalà¹, Barbara Merelli², Amedeo Indriolo³, Carlo Tondini²

Affiliations

¹ Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy. Electronic address: mariomandala@tin.it.
² Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
³ Unit of Gastroenterology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

PMID: 29559189
DOI: 10.1016/j.ejca.2018.02.019

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Disease
Acute Lung Injury / chemically induced
Acute Lung Injury / complications
Antineoplastic Agents, Immunological / adverse effects*
Cell Cycle Checkpoints / drug effects
Chemotherapy, Adjuvant
Female
Humans
Ipilimumab / administration & dosage
Ipilimumab / adverse effects*
Late Onset Disorders / chemically induced*
Lung Diseases, Interstitial / chemically induced*
Lung Diseases, Interstitial / complications
Melanoma / drug therapy*
Melanoma / pathology
Middle Aged
Neoplasm Staging
Protein Kinase Inhibitors / adverse effects
Randomized Controlled Trials as Topic
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Syndrome
Time Factors
Vulvar Neoplasms / drug therapy
Vulvar Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological
Ipilimumab
Protein Kinase Inhibitors